Topics: Rheumatoid Arthritis, GoBoldly
From accessing medicines to intellectual property to drug safety, PhRMA is devoted to advancing public policies that support innovative medical research, improve treatments and yield real results.
Catalyst-Logo-Featured-Image.jpg.
In the latest video of our Cells series, part of the GOBOLDLY™ campaign, we witness the destruction of a rogue cell that causes rheumatoid arthritis (RA), a disease that affects 1.3 million Americans.
RA is a painful and crippling autoimmune disease that is, simply put, the body’s own immune system attacking the joints. With this disease, normally beneficial immune cells, called B cells and T cells, go “rogue,” attacking joints and causing inflammation and pain.
Over the last decade, we’ve seen a number of advancements in treatments for RA, including a new first-in-class oral medicine offering greater convenience for patients. But researchers at America’s biopharmaceutical companies aren’t stopping there. They are working tirelessly to develop more weapons to combat and destroy these rogue cells, with the hope of one day giving patients the opportunity for a life free of pain.
Learn more about the fight against rheumatoid arthritis at GoBoldly.com and Innovation.org.
Topics: Rheumatoid Arthritis, GoBoldly
Pharmaceutical Research and Manufacturers of America®
950 F Street, NW Suite 300, Washington, DC 20004
Please be advised that this page contains pixel tags. To learn more about what pixel tags are, why and how
we and third parties use pixel tags, and how that use affects you, visit our privacy policy and review
"1. Information Collection."